Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47(phox-/-) mouse model of chronic granulomatous disease

Infection and Immunity

Volumn 68, Issue 4, 2000, Pages 2374-2378

  Segal, Brahm H ^a,d   Sakamoto, Nobuaki ^b,e   Patel, Mayur ^b,f   Maemura, Kosei ^b,g   Klein, Andrew S ^b   Holland, Steven M ^a   Bulkley, Gregory B ^b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d BUFFALO GENERAL HOSPITAL   (United States)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCIUM IONOPHORE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; XANTHINE OXIDASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BURKHOLDERIA CEPACIA; CATABOLISM; CELL KILLING; CHRONIC GRANULOMATOUS DISEASE; ESCHERICHIA COLI; GENOTYPE; HOST RESISTANCE; HYPOTHESIS; PRIORITY JOURNAL;

ALLOPURINOL; ANIMALS; BURKHOLDERIA CEPACIA; ESCHERICHIA COLI; FEMALE; FREE RADICAL SCAVENGERS; GENOTYPE; GRANULOMATOUS DISEASE, CHRONIC; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; PHAGOCYTES; PHOSPHOPROTEINS; XANTHINE OXIDASE;

EID: 0034117341     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.4.2374-2378.2000     Document Type: Article

References (41)

1. Abati, A., A. Cajigas, S. M. Holland, and D. Solomon. 1996. Chronic granulomatous disease of childhood: respiratory cytology. Diagn. Cytopathol. 15:98-102.
2. Babior, B. M. 1999. NADPH oxidase: an update. Blood 93:1464-1476.
3. Bulkley, G. B. 1997. Physiology of reactive oxidant-mediated signal transduction: an overview. Biochem. Soc. Trans. 25:804-812.
4. Bulkley, G. B. 1994. Reactive oxygen metabolites and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet 344:934-936.
5. phox / mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease. J. Clin. Investig. 101:1843-1850.
6. Dupont, G. P., T. P. Huecksteadt, B. C. Marshall, U. S. Ryan, J. R. Michael, and J. R. Hoidal. 1992. Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. J. Clin. Investig. 89:197-202.
7. Faggioni, R., S. Gatti, M. T. Demitri, R. Delgado, B. Echtenacher, P. Gnocchi, H. Heremans, and P. Ghezzi. 1994. Role of xanthine oxidase and reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema. J. Lab. Clin. Med. 123:394-399.
8. Falciani, F., P. Ghezzi, M. Terao, G. Cazzaniga, and E. Garattini. 1992. Interferons induce xanthine dehydrogenase gene expression in L929 cells. Biochem. J. 285:1001-1008.
9. Friedl, H. P., G. O. Till, U. S. Ryan, and P. A. Ward. 1989. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J. 3:2512-2518.
10. Gallin, J. I., E. S. Buescher, B. E. Seligmann, J. Nath, T. Gaither, and P. Katz. 1983. NIH conference. Recent advances in chronic granulomatous disease. Ann. Intern. Med. 99:657-674.
11. Gallin, J. I., J. M. Farber, S. M. Holland, and T. B. Nulman. 1915. Interferon-gamma in the management of infectious diseases. Ann. Intern. Med. 123:216-224.
12. Ghezzi, P., M. Blanchi, A. Mantovani, F. Spreafico, and M. Salmona. 1984. Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochem. Biophys. Res. Commun. 119:144-149.
13. Henderson, W. R., and S. J. Klebanoff. 1983. Leukotriene production and inactivation by normal, chronic granulomatous disease and myeloperoxidase-deficient neutrophils. J. Biol. Chem. 258:13522-13527.
14. The International Chronic Granulomatous Disease Cooperative Study Group. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324:509-516.
15. Jackson, S. H., J. I. Gallin, and S. M. Holland. 1995. The p47phox mouse knock-out model of chronic granulomatous disease. J. Exp. Med. 182:751-758.
16. Klein, A., M. Zhadkewich, J. Margolick, J. Winkelstein, and G. Bulkley. 1994. Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing. J. Leukoc. Biol. 55:248-252.
17. Klein, A. S., M. Zhadkevich, D. Wang, J. B. Margolick, J. A. Winkelstein, and G. B. Bulkley. 1996. Discriminant quantitation of posttransplant hepatic reticuloendothelial function. The impact of ischemic preservation. Transplantation 61:1156-1161.
18. phox-deficient model of chronic granulomatous disease. Blood 89:2258-2275.
19. Mayumi, T., C. K. Chan, M. G. Clemens, and G. B. Bulkley. 1996. Zonal heterogeneity of hepatic injury following shock/resuscitation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis. Shock 5:324-332.
20. Miles, A. M., D. S. Bohle, P. A. Glassbrenner, B. Hansert, D. A. Wink, and M. B. Grisham. 1996. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J. Biol. Chem. 271:40-47.
21. Muhlebach, T. J., H. J. Feickert, K. Welte, and R. A. Seger. 1991. Granulocyte-macrophage colony stimulating factor does not improve neutrophil oxidative metabolism in a patient with variant X-linked chronic granulomatous disease. Eur. J. Pediatr. 150:575-578.
22. Nathan, C. F., C. R. Horowitz, J. de la Harpe, S. Vadhan-Raj, S. A. Sherwin, H. F. Oettgen, and S. E. Krown. 1985. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl. Acad. Sci. USA 82:8686-8690.
23. Nathan, C. F., G. Kaplan, W. R. Levis, A. Nusrat, M. D. Witmer, S. A. Sherwin, C. K. Job, C. R. Horowitz, R. M. Steinman, and Z. A. Cohn. 1986. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N. Engl. J. Med. 315:6-15.
24. O'Neil, K. M., J. H. Herman, J. F. Modlin, E. R. Moxon, and J. A. Winkelstein. 1986. Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J. Pediatr. 108:940-942.
25. Parks, D. A., and D. N. Granger. 1986. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol. Scand. Suppl. 548:87-99.
26. Pfeffer, K. D., T. P. Huecksteadt, and J. R. Hoidal. 1994. Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation. J. Immunol. 153:1789-1797.
27. Pogrebniak, H. W., J. I. Gallin, H. L. Malech, A. R. Baker, C. A. Moskaluk, W. D. Travis, and H. I. Pass. 1993. Surgical management of pulmonary infections in chronic granulomatous disease of childhood. Ann. Thorac. Surg. 55:844-849.
28. Potoka, D. A., S. Takao, T. Owaki, G. B. Bulkley, and A. S. Klein. 1998. Endothelial cells potentiate oxidant-mediated Kupffer cell phagocytic killing. Free Radic. Biol. Med. 24:1217-1227.
29. Qu, X. W., R. A. Rozenfeld, W. Huang, G. B. Bulkley, and W. Hsueh. 1999. The role of xanthine oxidase in platelet activating factor induced intestinal injury in the rat. Gut 44:2113-211.
30. Roos, D. 1994. The genetic basis of chronic granulomatous disease. Immunol. Rev. 138:121-157.
31. Ross, J. P., S. M. Holland, V. J. Gill, E. S. DeCarlo, and J. I. Gallin. 1995. Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin. Infect. Dis. 21: 1291-1293.
32. Schiff, D. E., J. Rae, T. R. Martin, B. H. Davis, and J. T. Curnutte. 1997. Increased phagocyte Fc gammaRI expression and improved Fcγ-receptor-mediated phagocytosis after in vivo recombinant human interferon-γ treatment of normal human subjects. Blood 90:3187-3194.
33. Segal, B. H., E. S. DeCarlo, K. J. Kwon-Chung, H. L. Malech, J. I. Gallin, and S. M. Holland. 1998. Aspergillus nidulans infection in chronic granulomatous disease. Medicine 77:345-354.
34. Speert, D. P., M. Bond, R. C. Woodman, and J. T. Curnutte. 1994. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of non-oxidative killing by neutrophils in host defense. J. Infect. Dis. 170:1524-1531.
35. Sponseller, P. D., H. L. Malech, E. F. McCarthy, Jr., S. F. Horowitz, G. Jaffe, and J. I. Gallin. 1991. Skeletal involvement in children who have chronic granulomatous disease. J. Bone Jt. Surg. Am. Vol. 73:37-51.
36. Takao, S., E. H. Smith, D. Wang, C. K. Chan, G. B. Bulkley, and A. S. Klein. 1996. Role of reactive oxygen metabolites in murine peritoneal macrophage phagocytosis and phagocytic killing. Am. J. Physiol. 271:C1278-C1284.
37. Tauber, A. I., N. Borregaard, E. Simons, and J. Wright. 1983. Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies. Medicine 62:286-309.
38. Thrasher, A. J., N. H. Keep, F. Wientjes, and A. W. Segal. 1994. Chronic granulomatous disease. Biochim. Biophys. Acta 1227:1-24.
39. Tubaro, E., B. Lotti, C. Santiangeli, and G. Cavallo. 1980. Xanthine oxidase increase in polymorphonuclear leucocytes and macrophages in mice in three pathological situations. Biochem. Pharmacol. 29:1945-1948.
40. Umezawa, K., T. Akaike, S. Fujii, M. Suga, K. Setoguchi, A. Ozawa, and H. Maeda. 1997. Induction of nitric oxide synthesis and xanthine oxidase and their roles in the antimicrobial mechanism against Salmonella typhimurium infection in mice. Infect. Immun. 65:2932-2940.
41. Woodman, R. C., R. W. Erickson, J. Rae, H. S. Jaffe, and J. T. Curnutte. 1992. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 79:1558-1562.